美沙拉嗪肠溶片联合维生素D对溃疡性结肠炎患者肠道屏障功能和炎症因子的影响

doi:10.3969/j.issn.1671-7171.2025.07.022

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1234 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨美沙拉嗪肠溶片联合维生素D对溃疡性结肠炎(UC)患者肠道屏障功能和炎症因子的影响。【方法】选择2020年3月至2023年3月本院收治的96例UC患者,根据随机数字表法将其分为对照组和观察组,每组48例。对照组给予美沙拉嗪肠溶片治疗,观察组在对照组的基础上联合维生素D治疗。比较两组患者的临床疗效,治疗前后的肠道黏膜屏障功能指标[二胺氧化酶(DAO)、D-乳酸(D-LA)、肠型脂肪酸结合蛋白(I-FABP)]、肠道菌群(乳酸杆菌、双歧杆菌、肠杆菌)、炎症因子[肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)、白介素-6(IL-6)]、内镜下病变程度指标(Baron评分、Mayo评分)以及不良反应发生情况。【结果】观察组总有效率为97.92%(47/48),高于对照组的79.17%(38/48),差异有统计学意义(χ²=8.317,P<0.05)。治疗后,两组患者血清DAO、D-LA、I-FABP水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组肠杆菌数量低于治疗前,且观察组低于对照组,两组乳酸杆菌、双歧杆菌数量均高于治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05);两组血清TNF-α、IL-1β、IL-6水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组Baron评分、Mayo评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】美沙拉嗪肠溶片联合维生素D能够有效增强UC患者肠道黏膜屏障功能,降低炎症因子水平,调节肠道菌群,且安全性较高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	崔会宾
	刘晓恺
	冯伟

关键词 ：结肠炎, 溃疡性, 氨水杨酸, 维生素D, 炎症趋化因子类

Abstract：【Objective】To explore the effects of mesalazine enteric-coated tablets combined with vitamin D on intestinal barrier function and inflammatory factors in patients with ulcerative colitis (UC). 【Methods】 A total of 96 UC patients admitted to our hospital from March 2020 to March 2023 were selected and divided into the control group and the observation group according to the random number table method, with 48 cases in each group. The control group was treated with mesalazine enteric-coated tablets, and the observation group was treated with mesalazine enteric-coated tablets combined with vitamin D on the basis of the control group. The clinical efficacy, intestinal mucosal barrier function indexes [serum diamine oxidase (DAO), D-lactic acid (D-LA), intestinal fatty acid binding protein (I-FABP)], intestinal flora (lactobacillus, bifidobacterium, enterobacterium), inflammatory factors [tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6)], endoscopic lesion indexes (Baron score, Mayo score) and incidence of adverse reactions were compared between the two groups. 【Results】The total effective rate of the observation group was 97.92% (47/48), which was higher than 79.17% (38/48) of the control group, with a statistically significant difference (χ²=8.317, P<0.05). After treatment, the serum levels of DAO, D-LA and I-FABP in both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05); the number of enterobacteria in both groups was lower than that before treatment, and the observation group was lower than the control group; the numbers of lactobacillus and bifidobacterium in both groups were higher than those before treatment, and the observation group was higher than the control group, with statistically significant differences (P<0.05); the serum levels of TNF-α, IL-1β and IL-6 in both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05); the Baron score and Mayo score in both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Mesalazine enteric-coated tablets combined with vitamin D can effectively enhance the intestinal mucosal barrier function of UC patients, reduce the levels of inflammatory factors, regulate intestinal flora, and has high safety.

Key words： Colitis, Ulcerative Mesalamine Vitamin D Chemokines

收稿日期: 2024-02-19

中图分类号:

R574.62

引用本文:

崔会宾, 刘晓恺, 冯伟. 美沙拉嗪肠溶片联合维生素D对溃疡性结肠炎患者肠道屏障功能和炎症因子的影响[J]. 医学临床研究, 2025, 42(7): 1181-1184.
CUI Huibin, LIU Xiaokai, FENG Wei. Effects of Mesalazine Enteric-Coated Tablets Combined with Vitamin D on Intestinal Barrier Function and Inflammatory Factors in Patients with Ulcerative Colitis. JOURNAL OF CLINICAL RESEARCH, 2025, 42(7): 1181-1184.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.07.022 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I7/1181

[1] ARMUZZI A, LIGUORI G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review[J].Dig Liver Dis,2021, 53(7): 803-808.
[2] NANKI K, FUJII M, SHIMOKAWA M, et al. Somatic inflammatory gene mutations in human ulcerative colitis epithelium[J].Nature,2020, 577(7789): 254-259.
[3] 王晓瑜,缪志伟,张耀辉,等. 清肠汤联合美沙拉嗪治疗热盛血瘀型活动期溃疡性结肠炎患者的临床效果及其作用机制[J].中国医药导报,2022,19(19):115-119.
[4] 张小占,张雯,杨旋. 维生素D水平与溃疡性结肠炎患者TLR4/NF-κB信号通路及疾病活动度的相关性分析[J].中国现代医学杂志,2023,33(13):20-26.
[5] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018 年,北京)[J].中华消化杂志,2018,38(5):292-311.
[6] 刘丽,柳云恩. 溃疡性结肠炎患者血清miR-15表达水平与炎性反应状态及预后的关系[J].国际消化病杂志,2020,40(1):41-46.
[7] 宋泽军,董海滨,马娜,等. 改进的MAYO内镜评分对活动期溃疡性结肠炎疗效有较高的评估价值[J].南方医科大学学报,2023,43(7):1204-1213.
[8] DE OLIVEIRA N M T, SCHNEIDER V S, BUENO L R, et al. CPW partially attenuates DSS-induced ulcerative colitis in mice[J].Food Res Int,2023, 173: 113334.
[9] WU J, NIU J K, LI M J, et al. Keratin 1 maintains the intestinal barrier in ulcerative colitis[J].Genes Genomics,2021, 43: 1389-1402.
[10] DING Q H, FANG H, JIN P H, et al. Pretreating mesenchymal stem cells with IL-6 regulates the inflammatory response of DSS-induced ulcerative colitis in rats[J].Transpl Immunol,2023, 76: 101765.
[11] 张华,徐丽红,杨迪,等. 微生态制剂辅助美沙拉嗪治疗老年溃疡性结肠炎的疗效及对免疫功能炎症因子的影响[J].临床消化病杂志,2021,33(4):273-276.
[12] 马洋.美沙拉嗪肠溶片联合双歧三联活菌胶囊治疗溃疡性结肠炎疗效观察[J].中国中西医结合儿科学,2021,13(1):66-68.
[13] 王征,杨红,金梦,等. 维生素D受体对低氧下结肠细胞屏障蛋白的作用[J].中国医学科学院学报,2019,41(4):506-511.
[14] XIA Y L, CHEN H W, XIAO H L, et al. Immune regulation mechanism of vitamin D level and IL17/IL17R pathway in Crohn's disease[J].Exp Ther Med,2019, 17(5): 3423-3428.
[15] 刘超,林孟柯,孙冉冉. 调气通腑健脾方对脓毒症胃肠功能障碍患者外周血细胞因子、血内毒素水平及肠道机械屏障修复的影响[J].中国中医急症,2023,32(3):452-455.